Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent

Immunology and Cell Biology

Volumn 90, Issue 8, 2012, Pages 774-783

  Hillyer, Philippa ^a   Mane, Viraj P ^a,b   Schramm, Lynnsie M ^a   Puig, Montserrat ^a   Verthelyi, Daniela ^a   Chen, Aaron ^a   Zhao, Zeng ^a   Navarro, Maria B ^a   Kirschman, Kevin D ^a   Bykadi, Srikant ^a   Jubin, Ronald G ^a   Rabin, Ronald L ^a,c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b PBL InterferonSource   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

dendritic cell; interferon ; interferon l; qRT PCR; Toll like receptor

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DIFFERENTIATION ANTIGEN; DOUBLE STRANDED RNA; IMIQUIMOD; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA 3; INTERFERON TYPE III; INTERLEUKIN 28A; INTERLEUKIN 29; LIPOPOLYSACCHARIDE; LOCKED NUCLEIC ACID; MELANOMA DIFFERENTIATION ANTIGEN 5; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CELL TYPE; CONTROLLED STUDY; CPG ISLAND; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; MACROPHAGE; MOLECULAR BEACON; MOLECULAR PROBE; MONOCYTE; MONOCYTE DERIVED DENDRITIC CELL; MONOCYTE DERIVED MACROPHAGE; MYELOID DENDRITIC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; DENDRITIC CELLS; DNA PROBES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIGANDS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MYELOID CELLS; OLIGODEOXYRIBONUCLEOTIDES; ORGAN SPECIFICITY; POLY I-C; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TOLL-LIKE RECEPTORS;

EID: 84866428295     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.109     Document Type: Article

References (79)

1. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26: 112S-121S.
2. Koyama Y, Tanaka Y, Oda S, Yamashita U, Eto S. Antiviral and antiproliferative activities of recombinant human interferon alpha 2, beta and gamma on HTLV-I and ATL cells in vitro. J UOEH 1990; 12: 149-161.
3. Witter F, Barouki F, Griffin D, Nadler P, Woods A, Wood D et al. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers. Clin Pharmacol Ther 1987; 42: 567-575.
4. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2005; 2: 80.
5. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 2009; 106: 9010-9015.
6. Marth C, Windbichler GH, Hausmaninger H, Petru E, Estermann K, Pelzer A et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: Results of a phase I/II study. Int J Gynecol Cancer 2006; 16: 1522-1528.
7. Hirankarn N, Tangwattanachuleeporn M, Wongpiyabovorn J, Wongchinsri J, Avihingsanon Y. Genetic association of interferon-alpha subtypes 1, 2 and 5 in systemic lupus erythematosus. Tissue Antigens 2008; 72: 588-592.
8. Raad I, Hachem R, Leeds N, Sawaya R, Salem Z, Atweh S. Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin Infect Dis 1996; 22: 572-574.
9. Giosue S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000; 11: 99-104.
10. Bufe A, Gehlhar K, Grage-Griebenow E, Ernst M. Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol 2002; 127: 82-88.
11. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-267.
12. Isaacs A, Lindenmann J, Valentine RC. Virus interference II Some properties of interferon. Proc R Soc Lond B Biol Sci 1957; 147: 268-273.
13. Lindenmann J, Burke DC, Isaacs A. Studies on the production, mode of action and properties of interferon. Br J Exp Pathol 1957; 38: 551-562.
14. Rubinstein M, Rubinstein S, Familletti PC, Gross MS, Miller RS, Waldman AA et al. Human leukocyte interferon purified to homogeneity. Science 1978; 202: 1289-1290.
15. Rubinstein M. The purification and characterization of alpha interferons and related cytokine receptors-A personal account. Cytokine Growth Factor Rev 2007; 18: 519-524.
16. Nagata S, Mantei N, Weissmann C. The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha. Nature 1980; 287: 401-408.
17. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
18. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68.
19. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al. IFNlambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
20. Genin P, Vaccaro A, Civas A. The role of differential expression of human interferon-A genes in antiviral immunity. Cytokine Growth Factor Rev 2009; 20: 283-295.
21. Yanai Y, Sanou O, Kayano T, Ariyasu H, Yamamoto K, Yamauchi H et al. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions. J Interferon Cytokine Res 2001; 21: 835-841.
22. Foster GR, Rodrigues O, Ghouze F, Schulte-Frohlinde E, Testa D, Liao MJ et al. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res 1996; 16: 1027-1033.
23. Weck PK, Apperson S, May L, Stebbing N. Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures. J Gen Virol 1981; 57: 233-237.
24. Scagnolari C, Trombetti S, Selvaggi C, Carbone T, Monteleone K, Spano L et al. In vitro sensitivity of human metapneumovirus to type I interferons. Viral Immunol 2011; 24: 159-164.
25. Hilkens CM, Schlaak JF, Kerr IM. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 2003; 171: 5255-5263.
26. Hibbert L, Foster GR. Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J Interferon Cytokine Res 1999; 19: 309-318.
27. Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL et al. Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure 1996; 4: 1453-1463.
28. Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol 1997; 274: 661-675.
29. Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM et al. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: A potential role in systemic lupus erythematosus. J Immunol 2006; 177: 383-394.
30. Innan H, Kondrashov F. The evolution of gene duplications: Classifying and distinguishing between models. Nat Rev Genet 2010; 11: 97-108.
31. Woelk CH, Frost SD, Richman DD, Higley PE, Kosakovsky Pond SL. Evolution of the interferon alpha gene family in eutherian mammals. Gene 2007; 397: 38-50.
32. Tena-Tomas C, de Messias-Reason I, Song le H, Tomiuk J, Kemsner PG, Kun JF. A globally occurring indel polymorphism in the promoter of the IFNA2 gene is not associated with severity of malaria but with the positivity rate of HCV. BMC Genet 2008; 9: 80.
33. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
34. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
35. Chan A, Newman DL, Shon AM, Schneider DH, Kuldanek S, Ober C. Variation in the type I interferon gene cluster on 9p21 influences susceptibility to asthma and atopy. Genes Immun 2006; 7: 169-178.
36. Li Y, Zhou X, Ye D. Molecular beacons: An optimal multifunctional biological probe. Biochem Biophys Res Commun 2008; 373: 457-461.
37. Tyagi S, Kramer FR. Molecular beacons: Probes that fluoresce upon hybridization. Nat Biotechnol 1996; 14: 303-308.
38. Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M et al. LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 1998; 54: 3607-3630.
39. Mouritzen P, Nielsen AT, Pfundheller HM, Choleva Y, Kongsbak L, Moller S. Single nucleotide polymorphism genotyping using locked nucleic acid (LNA). Expert Rev Mol Diagn 2003; 3: 27-38.
40. Giesendorf BA, Vet JA, Tyagi S, Mensink EJ, Trijbels FJ, Blom HJ. Molecular beacons: A new approach for semiautomated mutation analysis. Clin Chem 1998; 44: 482-486.
41. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31: 3406-3415.
42. Zuker M DNA mfold server. The RNA Institute, College of Arts and Sceinces, University at Albany, State University of New York. Available from: Http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form
43. Hummelshoj L, Ryder LP, Madsen HO, Poulsen LK. Locked nucleic acid inhibits amplification of contaminating DNA in real-time PCR. Biotechniques 2005; 38: 605-610.
44. Hussain M, Gill DS, Liao MJ. Both variant forms of interferon-alpha4 gene (IFNA4a and IFNA4b) are present in the human population. J Interferon Cytokine Res 1997; 17: 559-566.
45. Uze G, Di Marco S, Mouchel-Vielh E, Monneron D, Bandu MT, Horisberger MA et al. Domains of interaction between alpha interferon and its receptor components. J Mol Biol 1994; 243: 245-257.
46. Juarez E, Nunez C, Sada E, Ellner JJ, Schwander SK, Torres M. Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res 2010; 11: 2.
47. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805.
48. Szubin R, Chang WL, Greasby T, Beckett L, Baumgarth N. Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells. J Interferon Cytokine Res 2008; 28: 749-763.
49. Hiscott J, Cantell K, Weissmann C. Differential expression of human interferon genes. Nucleic Acids Res 1984; 12: 3727-3746.
50. Nyman TA, Tolo H, Parkkinen J, Kalkkinen N. Identification of nine interferon-alpha subtypes produced by Sendai virus-induced human peripheral blood leucocytes. Biochem J 1998; 329(Pt 2): 295-302.
51. Mane VP, Heuer MA, Hillyer P, Navarro MB, Rabin RL. Systematic method for determining an ideal housekeeping gene for real-time PCR analysis. J Biomol Tech 2008; 19: 342-347.
52. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 2006; 25: 373-381.
53. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264.
54. Baig E, Fish EN. Distinct signature type I interferon responses are determined by the infecting virus and the target cell. Antivir Ther 2008; 13: 409-422.
55. Li L, Sherry B. IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection. Virology Jan 5; 396: 59-68.
56. Puig M, Tosh KW, Schramm LM, Grajkowska L, Kirschman KD, Tami C et al. CpG ODN and imiquimod induce distinct type I interferon responses in humans and non-human primates. J Leukoc Biol 2012; 91 (doi:10.1189/jlb.0711371).
57. Ablasser A, Poeck H, Anz D, Berger M, Schlee M, Kim S et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol 2009; 182: 6824-6833.
58. Kramer M, Schulte BM, Eleveld-Trancikova D, van Hout-Kuijer M, Toonen LW, Tel J et al. Cross-talk between human dendritic cell subsets influences expression of RNA sensors and inhibits picornavirus infection. J Innate Immun 2010; 2: 360-370.
59. Au WC, Moore PA, Lowther W, Juang YT, Pitha PM. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci USA 1995; 92: 11657-11661.
60. Izaguirre A, Barnes BJ, Amrute S, Yeow WS, Megjugorac N, Dai J et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 2003; 74: 1125-1138.
61. Genin P, Lin R, Hiscott J, Civas A. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol 2009; 29: 3435-3450.
62. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 2007; 179: 3434-3442.
63. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-777.
64. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25: 349-360.
65. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008; 26: 535-584.
66. Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, Fitzgerald-Bocarsly P et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J Biol Chem 2005; 280: 21078-21090.
67. Zhang L, Pagano JS. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol Cell Biol 1997; 17: 5748-5757.
68. Ozato K, Tailor P, Kubota T. The interferon regulatory factor family in host defense: Mechanism of action. J Biol Chem 2007; 282: 20065-20069.
69. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM et al. Virulence of a mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci USA 2001; 98: 5752-5757.
70. Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med 2004; 200: 535-540.
71. O'Connell RM, Saha SK, Vaidya SA, Bruhn KW, Miranda GA, Zarnegar B et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 2004; 200: 437-445.
72. Antonelli LR, Gigliotti Rothfuchs A, Goncalves R, Roffe E, Cheever AW, Bafica A et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 2010; 120: 1674-1682.
73. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-1115.
74. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004; 76: 314-321.
75. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215: 403-410.
76. Pfaffl MW. Quantification strategies in real-time PCR. In: Bustin SA (ed). A-Z of Quantitative PCR. International University Line: La Jolla, CA, 2004, pp 89-120.
77. Puig M, Grajkowski A, Boczkowska M, Ausin C, Beaucage SL, Verthelyi D. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: Structural studies and immunomodulatory activity in primates. Nucleic Acids Res 2006; 34: 6488-6495.
78. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34: 251-262.
79. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-622.